Sort
46,585 grants matching “heart failure”
Structure and function of voltage-gated calcium channels
$808,022Daniel L Minor · University Of California, San Francisco · R01 · FY2023 · HL
Structure and function of voltage-gated calcium channels
$808,022Daniel L Minor · University Of California, San Francisco · R01 · FY2022 · HL
TOPMed WGS and Molecular Epidemiology Analyses for Cardiac Hypertrophy Phenotypes
$807,948Ulrich Broeckel · Medical College Of Wisconsin · R56 · FY2023 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
$807,795David Richard Light · Illexcor Therapeutics, Llc · R44 · FY2024 · HL
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2020 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2021 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2022 · DK
Immunopathogenesis of HIV-associated pulmonary hypertension
$807,583Karen A Norris · University Of Georgia · R01 · FY2018 · HL
Improving Kidney Function Assessment in Health and Disease
$807,560Lesley Ann Inker · Tufts Medical Center · R01 · FY2021 · DK
Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy
$807,541Deok-Ho Kim · Johns Hopkins University · UG3 · FY2021 · TR
Ultrasound-Targeted Therapy for Acute Myocardial Infarction
$807,524Sanjiv Kaul · Oregon Health & Science University · R01 · FY2011 · HL
Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
$807,497Theodore P Abraham · University Of California, San Francisco · R01 · FY2022 · HL
Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
$807,497Theodore P Abraham · University Of California, San Francisco · R01 · FY2023 · HL
Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
$807,495Theodore P Abraham · University Of California, San Francisco · R01 · FY2025 · HL
Hypo-immunogenic cardiomyocytes for myocardial repair
$807,471Tobias Deuse · University Of California, San Francisco · R01 · FY2021 · HL
Using Data to Drive Change in National CV Care: The Duke CERTS
$807,365Eric David Peterson · Duke University · U19 · FY2011 · HS
Melanocortin 4 receptor agonists to treat sleep disordered breathing in obesity
$807,364Vsevolod Y Polotsky · George Washington University · R01 · FY2025 · HL
Melanocortin 4 receptor agonists to treat sleep disordered breathing in obesity
$807,364Vsevolod Y Polotsky · George Washington University · R01 · FY2024 · HL
Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
$807,362David Jackson · Ceria Therapeutics, Inc. · R44 · FY2023 · HL
Hyperpolarized 13C MRI of Cardiac Metabolic Remodeling in Heart Disease
$807,225Peder Eric Zufall Larson · University Of California, San Francisco · R01 · FY2025 · HL
Hyperpolarized 13C MRI of Cardiac Metabolic Remodeling in Heart Disease
$807,225Peder Eric Zufall Larson · University Of California, San Francisco · R01 · FY2024 · HL
MEKK3 signaling in hemogenic endothelium
$807,159Mark L Kahn · University Of Pennsylvania · R01 · FY2019 · HL
Novel physiomarkers of high-risk labored breathing for advance warning of clinical deterioration
$807,067Shrirang Mukund Gadrey · University Of Virginia · R01 · FY2025 · HL
Plasminogen activator inhibitor 1 (PAI1) as a therapeutic target for maternal endothelial dysfunction in preeclampsia
$806,978Molly E McAdow · Yale University · R01 · FY2025 · HL
Polymerase Inhibitors of Respiratory Syncytial Virus
$806,958Richard K. Plemper · Georgia State University · R01 · FY2020 · AI